<DOC>
	<DOCNO>NCT00003080</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy kill tumor cell . PURPOSE : Phase I trial study effectiveness sequential chemotherapy follow peripheral stem cell transplantation treat patient persistent platinum refractory stage III stage IV ovarian cancer .</brief_summary>
	<brief_title>Chemotherapy Followed Peripheral Stem Cell Transplantation Treating Patients With Persistent Platinum Refractory Stage III IV Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Establish feasibility treat patient persistent platinum refractory stage III IV ovarian cancer sequential high dose chemotherapy follow peripheral blood stem cell rescue . II . Determine maximum tolerate dose thiotepa give approach . OUTLINE : This dose escalate study thiotepa . Initial cytoreduction mobilization peripheral blood stem cell ( PBSC ) conduct FHCRC protocol 506.3 ( cyclophosphamide paclitaxel ) 506.3 ( cyclophosphamide etoposide ) . PBSC syngeneic twin collect accord FHCRC protocol 753.0 . Patients undergo leukapheresis . Patients remain bulky disease ( great 2 cm ) cytoreduction/mobilization may undergo surgical debulking . High dose chemotherapy begin 30-40 day last chemotherapy cytoreduction/mobilization regimen . Patients receive mitoxantrone IV infusion 15 minute day -7 -5 . Thiotepa IV administer day -4 -3 . Peripheral blood stem cell ( PBSC ) infusion occur day 0 . 60-90 day later , melphalan IV administer 60 minute day -3 . Patients undergo PBSC infusion day 0 . Patients enter cohort 3 . In absence dose-limiting toxicity ( DLT ) , subsequent cohort 3 patient receive escalate dos thiotepa schedule . If DLT observe 2 3 patient , next cohort patient receive treatment next low dose level . Once 12 patient treat particular dose level , dose declare maximum tolerated dose . After engraftment follow melphalan , patient receive oral tamoxifen twice day 5 year relapse . Patients follow every 3 month first year , every 6 month next 4 year , annually . PROJECTED ACCRUAL : 20-30 patient accrue 2 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven persistent platinum refractory stage III/IV ovarian cancer PATIENT CHARACTERISTICS : Age : 18 60 Performance status : Karnofsky 80100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 1.5 mg/mL , unless history Gilbert 's disease SGOT SGPT great 2 time upper limit normal Renal : Creatinine clearance least 50 mg/mL No history hemorrhagic cystitis Cardiovascular : No history coronary artery disease No poorly control arrhythmia myocardial infarction Left ventricle ejection fraction least 50 % Pulmonary : Diffusion capacity least 50 % Other : Not pregnant HIV negative No second malignancy last 5 year except basal carcinoma skin PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No history allergy chemotherapy drug Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
</DOC>